MK-8242

DRUG2 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

Acute Myelogenous Leukemia (AML)Solid Tumors

Phase 1

Study of MK-8242 Alone and in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia (P07649)

TerminatedNCT01451437

Merck Sharp & Dohme LLCAcute Myelogenous Leukemia (AML)

Start: 2011-11-18End: 2014-09-05Updated: 2018-08-27

Study of Safety and Pharmacokinetics of MK-8242 in Participants With Advanced Solid Tumors (P07650)

TerminatedNCT01463696

Merck Sharp & Dohme LLCSolid Tumors

Start: 2011-12-21End: 2015-10-15Updated: 2018-08-27

Related Papers

A phase I trial of the human double minute 2 (HDM2) inhibitor MK-8242 in patients (pts) with advanced solid tumors.

Journal of Clinical Oncology2015-05-2010 citations

A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML).

Journal of Clinical Oncology2015-05-206 citations